SBIR and STTR Success Story for
Lpath, Inc.

(Information Posted/Updated on 03/02/2010)

Lpath, Inc.
6335 Ferris Square, Suite A
San Diego, CA  92121

Contact:    Roger Sabbadini, VP and CFO
Phone:      858-678-0800 ext 109
Fax:          858-678-0900
E-mail:      rsabbadini@lpath.com
Web Site:  http://www.lpath.com

Project Title:  Development of therapeutic antibodies for cancer and age-related macular degeneration
Related Award(s):  2R44-CA110298-04;2R44EY018020-02; 1R43CA132395-01A2
Technology Developed:
San Diego-based Lpath is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit dyregulated bioactive lipids that contribute to diseases. Lpath's is in clinical trials with a humanized mAb directed against Sphingosine-1-Phosphate (S1P), a bioactive lipid that is dysregulated in age-related macular degeneration (AMD) and cancer.

Key Words:  antibodies as drugs, cancer, AMD, bioactive lipid targets, sphingosine-1-phosphate, LPA, Immune-Y2 process, ASONEP.
Uses of Technology/Products/Service:
ASONEP is the systemic formulation of Lpath's anti-S1P mAb (sonepcizumab) has recently completed Phase I safety trials in cancer. We believe that this antibody can be effective in reducing tumor cell proliferation and protection from apoptosis, tumor-associated angiogenesis, metastatic potential and resistance to chemotherapeutic agents. iSONEP is the ocular forumation of the same drug substance and has recently completed Phase I clinical trials in age-related macular degeneration.

Benefit to Company:
The SBIR grant process has been critical to the development of ASONEP and iSONEP and has resulted in a world-wide strategic partnership with Merck-Serono.

How Product Was Commercialized:
In October, 2008, Lpath entered into a world-wide exclussive partnership with the pharmaceutical company, Merck-Serono, who may take over full clincial development and the eventual marketing of ASONEP in the cancer disease arena. The ocular product, iSONEP and Lpath's Lpathomab and other programs have not yet been partnered.

Other Comments Related to Company's Success Story:
With the critical aid of the SBIR process, Lpath has evolved from a start-up incubated in an academic lab to a publicly-traded entity with an already established management team, complete with a scientific advisory board and two clinical advisory boards, provides evidence that we can handle the ever-changing management needs of a growing biotech company.

Past R&D and/or Sales from this Project:   $0
Estimated Future Annual R&D and/or Sales from this Project:   $$ 4 B